龙源期刊?/p>
http://www.qikan.com.cn
基于两阶?/p>
SFA
模型的中国医药企业技?/p>
创新效率研究
作者:尹述?/p>
陈立?/p>
来源:《软科学?/p>
2016
年第
05
?/p>
摘要:运用超越对数生产函数随机前沿模型,采用
2009
?/p>
2013
年中?/p>
103
家沪深医药上
市公司面板数据,在考虑创新时滞的情况下根据创新生成和创新转化的两阶段特点构建投入产
出指标体系,测算了两阶段的中国医药企业技术创新效率,分析了关键影响因素的作用。结?/p>
显示:中国医药上市公司的技术创新具有阶段性,创新生成阶段的资源利用率介于
39%
?/p>
46%
,创新转化阶段的效率损失不超?/p>
35%
,创新生成成果促进了创新成果转化;考虑时滞?/p>
的技术创新效率值(
1
年或
2
年)高于时滞?/p>
0
的技术创新效率值;企业技术行为、企业主?/p>
特征、企业外部环境对两阶段的技术创新效率发挥不一致的作用,部分因素的作用受到了时?/p>
的影响?/p>
关键词:医药行业;技术创新效率;随机前沿生产函数
DOI
?/p>
10.13956/j.ss.1001-8409.2016.05.12
中图分类号:
F062.4
?/p>
F273.1
文献标识码:
A
文章编号?/p>
1001-8409
?/p>
2016
?/p>
05-0054-05
Abstract
?/p>
With the Stochastic Frontier Production Function
?/p>
based on the panel data of 103
pharmaceutical listed companies from 2009 to 2013
?/p>
by building a system of inputoutput indicators
which reflect characteristics of innovation generation phase and innovation transformation phase
considering innovation lag
?/p>
this paper estimates pharmaceutical firms technological innovation
efficiency
?/p>
and analyses the critical influences. Results show that
?/p>
Chinese pharmaceutical listed
companies technological innovation efficiency show periodic features
?/p>
resource utilization in
innovation generation phase is between 39% 46%
?/p>
efficiency loss in innovation transformation stage
is less than 35%
?/p>
innovation generation promotes the transformation of innovative output
?/p>
the
technology innovation efficiency is higher if considering the lag
?/p>
1 year or 2 years
);
the influence
of technology behavior
?/p>
subject features and external environment on technological innovation
efficiency of the two stages are not consistent
?/p>
the effect of some factors is affected by the delay.
Key words
?/p>
pharmaceutical industry
?/p>
technological innovation efficiency
?/p>
stochastic frontier
production function
在中国建设国家创新体系的背景下,经济发展方式逐渐由要素驱动向创新驱动转变。对?/p>
兼具经济效益与社会效益的医药产业,一方面,中国医药产业已步入高速发展期,有望在
2020
年以前成为全球第二大药品市场?/p>